期刊文献+

NF-κB在抗人DR5抗体诱导白血病细胞系凋亡中的作用 被引量:2

Effect of NF-κB on apoptosis of leukemia cell line induced by anti-human DR monoclonal antibody
原文传递
导出
摘要 观察NF-κB在抗人DR5抗体mDRA-6诱导白血病细胞凋亡中的激活,探讨NF-κB在抗人DR5抗体诱导白血病细胞凋亡中的作用。提取细胞蛋白,间接ELISA法检测NF-κB的激活;预先应用NF-κB抑制剂孵育细胞1h,MTT及流式细胞术检测mDRA-6对白血病Jurkat和U937细胞系的凋亡率。结果:mDRA-6作用Jurkat和U937细胞15min,激活形式NF-κB(NF-κBP65)明显增高;10mg/L的mDRA-6作用Jurkat和U937细胞4h,流式细胞术检测细胞凋亡率分别为56.63%和34.14%,而预先用15μmol/L的NF-κB抑制剂处理细胞1h,mDRA-6所致的Jurkat和U937细胞凋亡率分别增加至75.51%和58.01%。mDRA-6诱导白血病Jurkat和U937细胞凋亡过程中激活NF-κB,激活的NF-κB抑制mDRA-6的肿瘤细胞凋亡诱导作用。 To observe the activation of nuclear factor κB (NF-κB)and to investigate the effect of NF-κB on the apoptosis of Jurkat and U937 cells induced by anti-human DR5 monoclonal antibody (mDRA-6),total proteins of Jurkat and U937 cells was extracted ,and the activated NF-κB of Jurkat and U937 cells was detected with indirect ELISA assay. The apoptotic rate of Jurkat and U937 cells inducing by mDRA-6 were detected by MTT and flow cytometry. It was demonstrated that the level of the activated NF-κB in Jurkat and U937 cells treated with mDRA-6 for 15 minutes was significantly increased,As demonstrated by flow cytometry,the apoptotic rates of Jurkat and U937 cells acted by 10 mg/L of mDRA-6 for 4 hours were 56.63% and 34.14%respectively and the pre-treatment of these two kind of cells with 15 μmol/L of mDRA-6 inhibitor for one hour rendered the apoptotic rates of the affected cells to increase up to 76.51% and 58.01% respectively. It is concluded that anti-human DR5 monoclonal antibody can induce the apoptosis of the leukemic Jurkat and U937 cells through the expression of activated NK-κB and its inhibitor can block this effect.
出处 《现代免疫学》 CAS CSCD 北大核心 2010年第4期328-332,共5页 Current Immunology
基金 国家自然科学基金资助项目(30571697)
关键词 核因子ΚB 单克隆抗体 凋亡 白血病细胞 nuclear factor κB monoclonal antibody apoptosis leukemic cell
  • 相关文献

参考文献17

  • 1Ammann JU, Haag C, Kasperczyk H, et al. Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-κB inhibition [J]. Int J Cancer, 2009,124:1301-1311.
  • 2刘广超,马远方,李淑莲,白慧玲,张军,卢峰,杜耀武,赵粤萍,都景芳.诱导细胞凋亡的抗hDR5单抗的研究[J].中华微生物学和免疫学杂志,2006,26(7):632-636. 被引量:13
  • 3张军,马远方,刘广超,李淑莲.抗人DR5单克隆抗体对人肝癌细胞系HepG2的凋亡作用[J].现代免疫学,2007,27(1):65-68. 被引量:8
  • 4刘广超,都景芳,王靖,赵鹏,白慧玲,李淑莲,张军,杜耀武,马远方.抗DR5抗体对食管鳞癌的细胞毒作用及机制[J].中国免疫学杂志,2008,24(6):512-517. 被引量:2
  • 5Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism [J].Cell, 1986, 47: 921-928.
  • 6Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor -κB blockade in multiple myeloma; therapeutic applications [J]. Blood, 2002, 99:4079-4086.
  • 7Kirchner D, Duyster J, Ottinann O, et al. Mechanisms of Bcr2 Abl2 mediated NF2 kappa B /Rel activation [J]. Exp Hematol, 2003, 31: 504-511.
  • 8Radhakrishnan SK, Kamalakaran S. Pro-apoptotic role of NF- kappa B: implications for cancer therapy [J]. Biochim Biophys Acta, 2006, 1766:53- 62.
  • 9Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B [J]. Sclence, 1996, 274: 784-787.
  • 10Wang CY, Mayo MW, Korneluk RG, et al. NF kappa B antiappotosis: induction of TRAF1 and TRAF2 and c-lAP1 and c-IAP2 to suppress caspase 8 activation [J]. Science, 1998, 281:1680 1683.

二级参考文献7

共引文献16

同被引文献35

  • 1刘广超,马远方,李淑莲,白慧玲,张军,卢峰,杜耀武,赵粤萍,都景芳.诱导细胞凋亡的抗hDR5单抗的研究[J].中华微生物学和免疫学杂志,2006,26(7):632-636. 被引量:13
  • 2Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling biology and potential for cancer therapy [J]. Cytokine Growth Factor Rev, 2003,14:337-348.
  • 3Duiker EW, Morn CH, Jong S, et al. The clinical trail of TRAIL[J]. Eur J Cancer, 2006,42:2233-2240.
  • 4M rino D, Lalaoui N, Morizot A, et al. Differential inhibi- tion of TRAIL-mediated DR5-DISC formation by decoy re- ceptors 1 and 2[J]. Mol Cell Biol, 2006,26 : 7046-7055.
  • 5Varfolomeev E, Maecker H, Sharp D, et al. Molecular de- terminants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand[J]. J Biol Chem, 2005,280 : 40599-40608.
  • 6Pennarun B, Meijer A, de Vries EG, et al. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in canc- er[J]. Biochim Biophys Acta, 2010,1805 : 123-140.
  • 7Walczak H, Haas TL. Biochemical analysis of the native TRAIL death-inducing signaling complex[J]. Methods Mol Biol, 2008,414:221-239.
  • 8Koschny R, Walczak H, Ganten TM. The promise of TRAIL- potential and risks of a novel anticancer therapy[J]. J Mol Med, 2007,85:923-935.
  • 9Zhang LD, Fang BL. Mechanisms of resistance to TRAIL-in- duced aoptosis in cancer[J]. Cancer Gene Ther, 2005, 12: 228-237.
  • 10Greco F A, Bonomi P, Craw ford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which target sand activates the TRAIL receptor 1 inpatients with advanced nonsmall cell[J]. Lung Cancer, 2008,61:82-90.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部